Wall Street is positive on Nabriva Therapeutics PLC - ADR (NBRV). On average, analysts give Nabriva Therapeutics PLC - ADR a Buy rating. The average price target is $18, which means analysts expect the stock to rise by 659.49% over the next twelve months. That average ranking earns Nabriva Therapeutics PLC - ADR an Analyst Rating of 32, which is better than 32% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating NBRV a Buy today. Find out what this means to you and get the rest of the rankings on NBRV!